Tesamorelin

Tesamorelin is a 44-residue human GRF analogue bearing an N-(trans-3-hexenoyl) group and C-terminal amide. Drug substance is commonly handled as a multi-acetate material, so acetate stoichiometry, N-acylation and intact mass must be verified for the supplied batch [1–3].

Chemical properties and registry information

Registry values apply only to the specific molecular entity, sequence, termini and material form. Batch records take precedence over family-level literature identifiers.

A stabilized analogue of GHRH. The N-terminal modification protects the peptide from degradation by dipeptidyl peptidase-4 (DPP-4), extending its half-life and duration of action.

Research background and published evidence

Published research

Defined contexts include human GHRH-receptor binding and signalling, N-acylation structure–activity comparison, intact-mass and counter-ion analysis, and analytical separation from shorter GRF fragments [1–3].

Current scientific understanding

Regulatory and clinical documents describe separately manufactured medicinal material and do not authenticate this catalogue batch. They must not be converted into human-use, efficacy, safety or dosing claims.

Tesamorelin is an approved medicinal active substance in some jurisdictions.

Technical comparison

Quality and testing

Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot or similarly named material must not be treated as evidence for this product.

Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.

Laboratory handling and storage

Store and handle only under the conditions stated on the product label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination. Do not infer storage, solvent compatibility or stability from a related compound.

Laboratory preparation, analytical-method selection, risk assessment, personal protective equipment and waste disposal should follow the applicable SDS and the institution’s approved procedures.

Regulatory and legal status

Sources and references

1. [1] U.S. FDA chemistry review for tesamorelin.
2. [2] PubChem. Tesamorelin compound record.
3. [3] DailyMed. Tesamorelin product information.

Frequently Asked Questions

Do the CAS number and PubChem CID apply to every batch form?

Only when the exact sequence or structure, termini, conjugation, salt or counter-ion and hydration state match. The batch CoA and SDS govern; a related-compound identifier must not be substituted.

What does an analytical purity result mean?

It is method- and report-specific. For example, an HPLC area percentage is not automatically the same as identity, net content, sterility, endotoxin status or absence of elemental impurities.

How should the material be stored and handled?

Follow the exact label, batch CoA and SDS together with the institution’s risk assessment. Use only storage and stability information linked to the exact material form and batch.